Login / Signup

Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.

Lucas Antonio Duarte NicolauIsabela R S G NolêtoJand Venes Rolim Medeiros
Published in: Expert review of clinical pharmacology (2020)
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • nuclear factor
  • angiotensin ii
  • angiotensin converting enzyme
  • human health
  • adverse drug
  • drug induced
  • toll like receptor
  • climate change